Abstract
Keywords
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Colorectal CancerReferences
- Epidemiologic trends of and factors associated with overall survival for patients with gastroenteropancreatic neuroendocrine tumors in the united states.JAMA Netw Open. 2021; 4e2124750
- Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the united states.JAMA Oncol. 2017; 3: 1335-1342
- Pancreatic neuroendocrine tumors: biology, diagnosis,and treatment.Chin J Cancer. 2013; 32: 312-324
- Digestive well-differentiated grade 3 neuroendocrine tumors: current management and future directions.Cancers (Basel). 2021; : 13
- Lanreotide in metastatic enteropancreatic neuroendocrine tumors.N Engl J Med. 2014; 371: 1556-1557
- Everolimus for advanced pancreatic neuroendocrine tumors.N Engl J Med. 2011; 364: 514-523
- Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.N Engl J Med. 2011; 364: 501-513
- N.-T., phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors.N Engl J Med. 2017; 376: 125-135
- Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors.Clin Cancer Res. 2017; 23: 4617-4624
- Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study.Lancet Oncol. 2020; 21: 1489-1499
- A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN cancer research group (E2211).Journal of Clinical Oncology. 2018; 36 (-4004): 4004
- Chemotherapy in neuroendocrine tumors.Cancers (Basel). 2021; 13
- Comparison of design, eligibility, and outcomes of neuroendocrine neoplasm trials initiated from 2000 to 2009 vs 2010 to 2020.JAMA Netw Open. 2021; 4e2131744
- Medical management of gastroenteropancreatic neuroendocrine tumors.Surg Oncol Clin N Am. 2020; 29: 293-316
- Comparison of the therapeutic response to treatment with a 177Lu-Labeled somatostatin receptor agonist and antagonist in preclinical models.J Nucl Med. 2016; 57: 260-265
- Somatostatin and other Peptide receptors as tools for tumor diagnosis and treatment.Neuroendocrinology. 2004; 80: 51-56
- Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches.Clin Cancer Res. 2013; 19: 2842-2849
- Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.J Clin Oncol. 2009; 27: 4656-4663
- Progression-free survival (PFS) with lanreotide autogel/depot (LAN) in enteropancreatic NETs patients: The CLARINET extension study.Journal of Clinical Oncology. 2014; 32 (-4107): 4107
- Tumor response in the CLARINET study of lanreotide depot vs. placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).Journal of Clinical Oncology. 2016; 34 (-434): 434
- Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results.Eur J Cancer. 2021; 157: 403-414
- The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study.Ann Oncol. 2001; 12: 941-945
- Yttrium-90 DOTATOC: first clinical results.Eur J Nucl Med. 1999; 26: 1439-1447
- Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience.Semin Nucl Med. 2002; 32: 110-122
- Long-term efficacy, survival, and safety of.[Clin Cancer Res. 2017; 23: 4617-4624
- Targeted α-Emitter therapy of neuroendocrine tumors.Semin Nucl Med. 2020; 50: 171-176
- (177)Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors.Expert Rev Gastroenterol Hepatol. 2019; 13: 1023-1031
- Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors.Journal of Clinical Oncology. 2021; 39 (-4112): 4112
- Symptomatic and radiological response to 177Lu-DOTATATE for the treatment of functioning pancreatic neuroendocrine tumors.J Clin Endocrinol Metab. 2019; 104: 1336-1344
- Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours.Eur J Nucl Med Mol Imaging. 2014; 41: 925-933
- Afinitor (everolimus) [package insert].Novartis Pharmaceuticals Corporation, East Hanover, NJ2018 (2018)
- Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway.J Clin Oncol. 2010; 28: 245-255
- Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: overall survival and circulating biomarkers from the randomized, phase III RADIANT-3 study.J Clin Oncol. 2016; 34: 3906-3913
- Sutent (sunitinib malate) [package insert].Pfizer Labs, New York, NY2011 (2011)
- Molecular basis for sunitinib efficacy and future clinical development.Nat Rev Drug Discov. 2007; 6: 734-745
- New strategies for advanced neuroendocrine tumors in the era of targeted therapy.Clin Cancer Res. 2012; 18: 1830-1836
- In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.Clin Cancer Res. 2003; 9: 327-337
- Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.J Clin Oncol. 2006; 24: 25-35
- Activity of sunitinib in patients with advanced neuroendocrine tumors.J Clin Oncol. 2008; 26: 3403-3410
- O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.Clin Cancer Res. 2009; 15: 338-345
- Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas.J Clin Oncol. 2004; 22: 4762-4771
- Temozolomide alone or combined with capecitabine for the treatment of advanced pancreatic neuroendocrine tumor.Neuroendocrinology. 2020; 110: 83-91
- First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.Cancer. 2011; 117: 268-275
- Efficacy and toxicity analysis of capecitabine and temozolomide in neuroendocrine neoplasms.J Natl Compr Canc Netw. 2021; 20: 29-36
- High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy.Endocr Relat Cancer. 2016; 23: L17-L23
- Efficacy of FOLFOX in patients with aggressive pancreatic neuroendocrine tumors after prior capecitabine/temozolomide.Oncologist. 2021; 26: 115-119
- Oxaliplatin and 5-Fluorouracil in advanced well-differentiated digestive neuroendocrine tumors: a multicenter national retrospective study from the french group of endocrine tumors.Neuroendocrinology. 2021; 112: 537-546
- A clinical score for neuroendocrine tumor patients under consideration for Lu-177-DOTATATE therapy.Endocr Relat Cancer. 2021; 28: 203-212
- External validation of a clinical score for patients with neuroendocrine tumors under consideration for peptide receptor radionuclide therapy.JAMA Netw Open. 2022; 5e2144170
- Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.Semin Nucl Med. 2002; 32: 133-140
- Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size.J Nucl Med. 2001; 42: 1841-1846
- PRRT genomic signature in blood for prediction of (177)Lu-octreotate efficacy.Eur J Nucl Med Mol Imaging. 2018; 45: 1155-1169
- (2)(1)(3)Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience.Eur J Nucl Med Mol Imaging. 2014; 41: 2106-2119
- Targeted alpha-emitter therapy with (212)Pb-DOTAMTATE for the treatment of metastatic SSTR-expressing neuroendocrine tumors: first-in-human, dose-escalation clinical trial.J Nucl Med. 2022; (Online only publication: jnumed.121.263230)
- Broadening horizons with (225)Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to (177)Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety.Eur J Nucl Med Mol Imaging. 2020; 47: 934-946
- Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors.Ther Adv Med Oncol. 2021; 1317588359211018047
- Phase I trial of well-differentiated neuroendocrine tumors (NETs) with radiolabeled somatostatin antagonist (177)Lu-Satoreotide tetraxetan.Clin Cancer Res. 2019; 25: 6939-6947
- The next generation of peptide receptor radionuclide therapy.Endocr Relat Cancer. 2019; 26: C7-C11
- Potentiation of peptide receptor radionuclide therapy by the PARP inhibitor olaparib.Theranostics. 2016; 6: 1821-1832
- Activation of DNA-PK by ionizing radiation is mediated by protein phosphatase 6.PLoS One. 2009; 4: e4395
- ETCTN 10450: a Phase 1 Trial of Peposertib and Lutetium Lu 177 Dotatate in Well- differentiated Somatostatin Receptor- positive Neuroendocrine Tumors.in: NANETS 2021 Symposium Abstracts. 2021
- Ribonucleotide reductase inhibitors: a new look at an old target for radiosensitization.Front Oncol. 2011; 1: 56
- Etctn 10388: A phase I trial of triapine and lutetium Lu 177 dotatate in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).Journal of Clinical Oncology. 2020; 38 (-TPS4660): TPS4660
- Surufatinib: first approval.Drugs. 2021; 81: 727-732
- Interim analysis results of surufatinib in U.S. patients with neuroendocrine tumors (NETs).Journal of Clinical Oncology. 2021; 39 (-4114): 4114
- Emerging treatment options for gastroenteropancreatic neuroendocrine tumors.J Clin Med. 2020; 9
Limited H M, BeiGene, surufatinib in combination with tislelizumab in subjects with advanced solid tumors. https://ClinicalTrials.gov/show/NCT04579757: 2021.
- Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors (pNET).Journal of Clinical Oncology. 2017; 35 (-228): 228
Testing cabozantinib in patients with advanced pancreatic neuroendocrine and carcinoid tumors. https://ClinicalTrials.gov/show/NCT03375320. 2022
- Lenvatinib in patients with advanced grade 1/2 pancreatic and gastrointestinal neuroendocrine tumors: results of the phase II TALENT trial (GETNE1509).J Clin Oncol. 2021; 39: 2304-2312
- Efficacy and safety of pembrolizumab in previously treated advanced neuroendocrine tumors: results from the phase II KEYNOTE-158 study.Clin Cancer Res. 2020; 26: 2124-2130
- Spartalizumab in metastatic, well/poorly-differentiated neuroendocrine neoplasms.Endocr Relat Cancer. 2021; (ERC-20-0382.R1)
- Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma.N Engl J Med. 2019; 380: 1116-1127
- Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.N Engl J Med. 2020; 382: 1894-1905
- A phase II trial of atezolizumab and bevacizumab in patients with advanced, progressive neuroendocrine tumors (NETs).Journal of Clinical Oncology. 2020; 38 (-619): 619
Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumors. https://ClinicalTrials.gov/show/NCT03290079. 2022
- Targeting the somatostatin receptor 2 with the miniaturized drug conjugate, PEN-221: a potent and novel therapeutic for the treatment of small cell lung cancer.Mol Cancer Ther. 2019; 18: 1926-1936
- Discovery of an SSTR2-Targeting maytansinoid conjugate (PEN-221) with potent activity in vitro and in vivo.J Med Chem. 2019; 62: 2708-2719
- First in human phase 1/2a study of PEN-221 somatostatin analog (SSA)-DM1 conjugate for patients (PTS) with advanced neuroendocrine tumor (NET) or small cell lung cancer (SCLC): Phase 1 results.Journal of Clinical Oncology. 2018; 36 (-4097): 4097
- The safety and efficacy of PEN-221 somatostatin analog (SSA)-DM1 conjugate in patients (PTS) with advanced GI mid-gut neuroendocrine tumor (NET): Phase 2 results.Journal of Clinical Oncology. 2021; 39 (-4110): 4110
- The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types.Cancer. 2020; 126: 3192-3201
A study of XmAb®18087 in subjects with NET and GIST. https://ClinicalTrials.gov/show/NCT03411915. 2022
el-Rayes S P, V Villalobos, A Hendifar, et al. Preliminary safety, PK/PD, and antitumor activity of XmAb18087, an SSTR2 x CD3 bispecific antibody, in patients with advanced neuroendocrine tumors. NANETS 2020 Symposium Abstracts2020.
- Molecular signatures and their clinical utility in pancreatic neuroendocrine tumors.Front Endocrinol (Lausanne). 2020; 11575620
- Belzutifan: first approval.Drugs. 2021; 81: 1921-1927
- Phase 2 study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).Journal of Clinical Oncology. 2021; 39 (-4555): 4555
Belzutifan/MK-6482 for the treatment of advanced pheochromocytoma/paraganglioma (PPGL) or pancreatic neuroendocrine tumor (pNET) (MK-6482-015). https://ClinicalTrials.gov/show/NCT04924075. 2022
- Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased cdk4/cdk6.Clin Cancer Res. 2012; 18: 4612-4620
- Cyclin-dependent kinases 4/6 inhibitors in neuroendocrine neoplasms: from bench to bedside.Curr Oncol Rep. 2022;
- Cell cycle protein expression in neuroendocrine tumors: ssociation of CDK4/CDK6, CCND1, and phosphorylated retinoblastoma protein with proliferative index.Pancreas. 2017; 46: 1347-1353
- The PALBONET trial: a phase II study of palbociclib in metastatic grade 1 and 2 pancreatic neuroendocrine tumors (GETNE-1407).Oncologist. 2020; 25: 745-e1265
- The novel cyclin-dependent kinase 4/6 inhibitor ribociclib (LEE011) alone and in dual-targeting approaches demonstrates antitumoral efficacy in neuroendocrine tumors in vitro.Neuroendocrinology. 2018; 106: 58-73
- A pilot study of the cyclin dependent kinases 4, 6 inhibitor ribociclib in patients with foregut neuroendocrine tumors.in: NANETS 2018 Symposium Abstracts. 2018